Abstract:Heterozygous mutations in the PINK1 gene are considered a susceptibility factor to develop early-onset Parkinson's disease (PD), as supported by dopamine hypometabolism in asymptomatic mutation carriers and subtle alterations of dopamine-dependent striatal synaptic plasticity in heterozygous PINK1 knockout (PINK1(+/-)) mice. The aim of the present study was to investigate whether exposure to low-dose rotenone of heterozygous PINK1(+/-) mice, compared to their wild-type PINK1(+/+) littermates, could impact on dopamine-dependent striatal synaptic plasticity, in the absence of apparent structural alterations. Mice were exposed to a range of concentrations of rotenone (0.01-1mg/kg). Chronic treatment with concentrations of rotenone up to 0.8mg/kg did not cause manifest neuronal loss or changes in ATP levels both in the striatum or substantia nigra of PINK1(+/-) and PINK1(+/+) mice. Moreover, rotenone (up to 0.8mg/kg) treatment did not induce mislocalization of the mitochondrial membrane protein Tom20 and release of cytochrome c in PINK1(+/-) striata. Accordingly, basic electrophysiological properties of nigral dopaminergic and striatal medium spiny neurons (MSNs) were normal. Despite the lack of gross alterations in neuronal viability in chronically-treated PINK1(+/-), a complete loss of both long-term depression (LTD) and long-term potentiation (LTP) was recorded in MSNs from PINK1(+/-) mice treated with a low rotenone (0.1mg/kg) concentration. Even lower concentrations (0.01mg/kg) blocked LTP induction in heterozygous PINK1(+/-) MSNs compared to PINK1(+/+) mice. Of interest, chronic pretreatment with the antioxidants alpha-tocopherol and Trolox, a water-soluble analog of vitamin E and powerful antioxidant, rescued synaptic plasticity impairment, confirming that, at the doses we utilized, rotenone did not induce irreversible alterations. In this model, chronic exposure to low-doses of rotenone was not sufficient to alter mitochondrial integrity and ATP production, but profoundly impaired the expression of long-term plasticity at corticostriatal synapses in PINK1 heterozygous knockout mice, suggesting that disruption of synaptic plasticity may represent an early feature of a pre-manifesting state of the disease, and a potential tool to test novel neuroprotective agents.

Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in C. elegans: the role of mitochondria-associated membrane proteins in Parkinsonism.

Identification of Novel Proteins Affected by Rotenone in Mitochondria of Dopaminergic Cells

Mitochondrial Mechanism of Mutation in PINK1 Enhancing Neurotoxicity to Parkinsonian Toxicants

Loss of PINK1 causes age-dependent mitochondrial trafficking deficits in nigrostriatal dopaminergic neurons through aberrant activation of p38 MAPK

PARK6 PINK1 Mutants Are Defective in Maintaining Mitochondrial Membrane Potential and Inhibiting ROS Formation of Substantia Nigra Dopaminergic Neurons

Mitochondrial dysfunction and NDUFS3: Insights from a PINK1B9 Drosophila model in Parkinson's disease pathogenesis

Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice

Pink1 Defect Causes Mitochondrial Dysfunction, Proteasomal Deficit And Alpha-Synuclein Aggregation In Cell Culture Models Of Parkinson'S Disease

The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1α Regulates Rotenone-Induced Dopaminergic Neurotoxicity

PINK1/Parkin-mediated Mitophagy Play a Protective Role in Manganese Induced Apoptosis in SH-SY5Y Cells.

PINK1-PRKN mediated mitophagy: differences between in vitro and in vivo models

Subcellular localization and function analysis of PINK1 mitron in PD progression: Mitron modulates mitochondrial morphology to regulate neuronal death

Increased cysteine metabolism in PINK1 models of Parkinson's disease

Antioxidants Protect Pink1-Dependent Dopaminergic Neurons In Drosophila

Mutant-TMEM230-induced neurodegeneration and impaired axonal mitochondrial transport

Mitochondrial Complex I Inhibition in Dopaminergic Neurons Causes Altered Protein Profile and Protein Oxidation: Implications for Parkinson's disease

PINK1 Loss-of-Function Mutations Affect Mitochondrial Complex I Activity via NdufA10 Ubiquinone Uncoupling

PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease

PINK1/Parkin-mediated mitophagy in neurodegenerative diseases

Antioxidants protect <i>PINK1</i> -dependent dopaminergic neurons in <i>Drosophila</i>

Inhibition of Mir-421 Preserves Mitochondrial Function and Protects Against Parkinson’s Disease Pathogenesis Via Pink1/Parkin-Dependent Mitophagy